Study Subjects Design Dose Outcomes
Duan K, et al.191 China 10 Severe disease, ICU no MV
Pilot study, single center. Compared to historic control group
200 ml CP with neutralizing antibody titers >1:640
Increase in neutralizing antibodies. Improvement of symptoms. Increase in oxyhemoglobin saturation at d 3. Decrease CRP. No severe side effects. Reduction of deaths compared to historic control (p 0.001)
Shen C, et al.277 China 5 Critical disease, all in ICU + MV
Uncontrolled. Case series, single center
400 ml CP with titer > 1:1000 and neutralizing antibody titer >40
4/5: ARDS resolved within 12 d 5/5: Pao2/Fio2 increased within 12 d 5/5: SARS-CoV-2 RNA load negative at d 12 3/5: discharged from hospital at date of publication (51-55 d post infusion)
Zhang B, et al.278 China 4 Critical disease, ICU + MV
Uncontrolled. Case series
200 - 400 ml CP (does not specify neutralizing antibody titer) 4/4 clinical improvement and able to extubate 3/4 discharged from hospital at date of publication (24-33 d post infusion)
Ahn JY, et al.279 South Korea 2 Critical disease, ICU + MV
Case series
250 ml, 2 doses 12 h apart, (does not specify neutralizing antibody titer)
Radiological and clinical improvement. Decrease in viral load
Ye M, et al.280 China 6 Non-critically ill
Case series
200 - 600 ml CP (does not specify neutralizing antibody titer)
Radiological and clinical improvement
Zeng QL et al.281 China 21 ICU patients 6: active CP 15: controls
Case series Non-randomized.Controls did not have a match for CP
200 - 400 ml CP (does not specify neutralizing antibody titer) Increase in viral clearance in the CP vs controls. [CP 5/5, Controls 3/14 (p 0.005)] Increase survival period in CP patients (p 0.029) but there was high mortality in both groups, [CP 5/6, controls 14/15]
Schulman K. (PI) USA
Estimated enrollment: 206 patients visiting the ED
Phase 2 trial. Randomized, double blinded, controlled. CP vs placebo in adults with COVID-19 in an ED
200 - 600 ml CP with neutralizing antibody titers >1:80
Stanford University Ongoing NCT04355767
Shoham S. (PI) USA
Estimated enrollment: 150 subjects exposed to COVID-19
Phase 2 trial. Randomized, triple blinded, controlled. CP vs placebo. Adults in close contact exposure to a person with COVID-19 within 96 h of enrollment (and 120 h of receipt of plasma)
200 ml CP with neutralizing antibody titers >1:64
Johns Hopkins University Ongoing NCT04323800
Perotti C. (PI) Italy
Estimated enrollment: 46 COVID-19 patients with moderate-severe ARDS for < 10 d and need for MV
Longitudinal non-randomized non-controlled
250-300 ml of CP 3 times/d over 5 d (neutralizing antibody titer not specified) Foundation IRCCS San Matteo Hospital Ongoing NCT04321421
Menichetti F. (PI) Italy
Estimated enrollment: 126 COVID-19 patients hospitalized due to pneumonia with PaO2/FiO2 ratio 200-350 but not in MV
Phase 2 Trial. Multicenter prospective randomized open-label trial (CP vs standard therapy
200 ml of CP (neutralizing antibody titer not specified) Azienda Ospedaliero, Universitaria Pisana Ongoing NCT04393727